Company Narratives

Shifa International Hospitals Q1 FY2027: group revenue grew, but margins weakened

SHFA grew revenue on both standalone and consolidated bases, but group margins and earnings fell as costs and finance charges rose.

Shifa International Hospitals Q1 FY2027: group revenue grew, but margins weakened

Verdict: Shifa International Hospitals Limited delivered a two-sided Q1 FY2027 result. The standalone hospital business increased both revenue and profit after tax, but the consolidated group reported a much weaker conversion of revenue into earnings. Consolidated revenue rose 22.2% year on year, yet gross profit fell 27.7% and profit attributable to the parent declined 18.4%. The result therefore shows continued expansion, but also a material cost burden and a widening difference between standalone and consolidated profitability that need to be understood before the revenue growth can be treated as higher-quality growth.

The reporting basis matters. PSX’s company table presents the standalone headline result: revenue of Rs8.642 billion and profit after tax of Rs804.5 million. The consolidated accounts include the parent and subsidiaries, producing revenue of Rs9.303 billion but only Rs509.5 million of total group profit after tax; Rs604.9 million was attributable to the parent’s shareholders because non-controlling interests absorbed part of the group loss. Comparing the two bases mechanically would be misleading.

Results at a glance

  • Period and basis: unaudited first quarter ended September 30, 2026. The analysis separates standalone and consolidated figures; amounts are in Pakistani rupees.
  • Standalone revenue rose 13.5% to Rs8.642 billion from Rs7.616 billion, while standalone profit after tax increased 8.2% to Rs804.5 million from Rs743.6 million.
  • Consolidated revenue increased 22.2% to Rs9.303 billion from Rs7.616 billion, but consolidated gross profit fell 27.7% to Rs888.4 million.
  • Consolidated gross margin compressed to 9.55% from 16.14%, a decline of 6.59 percentage points.
  • Consolidated profit before tax fell 31.5% to Rs840.1 million; total group profit after tax fell 31.3% to Rs509.5 million.
  • Profit attributable to shareholders of Shifa International Hospitals was Rs604.9 million, down 18.4% from Rs741.0 million. Consolidated EPS was Rs9.56 versus Rs11.73.
  • No interim dividend was announced with the Q1 result.

The central issue: growth did not translate into consolidated profit

The group added approximately Rs1.687 billion of revenue year on year, but cost of services increased by about Rs2.028 billion. That adverse difference pushed consolidated gross profit down by Rs340.6 million. The arithmetic is unambiguous: the group’s cost base expanded faster than revenue, and the gross margin fell from 16.14% to 9.55%.

The current sources do not provide a quarter-specific bridge for patient volumes, occupancy, tariff increases, specialty mix, physician share, medicine costs or staffing costs. It would therefore be speculative to assign the margin decline to any one of those factors. The supported conclusion is narrower: expansion and service delivery generated strong top-line growth, but the incremental revenue carried substantially lower gross profitability.

Reported consolidated operating profit was Rs966.8 million, down 21.3% from Rs1.229 billion. Operating margin narrowed to 10.39% from 16.14%. The operating figure was slightly above gross profit because the reporting series includes other operating components, so it should not be treated as a simple gross-profit-minus-overheads subtotal without the full note reconciliation.

Finance cost rose 50.8% to Rs126.7 million from Rs84.0 million. Other income increased 9.8% to Rs118.6 million, but that was not enough to offset weaker operating profitability and higher finance charges. Profit before tax fell to Rs840.1 million from Rs1.226 billion.

Standalone resilience versus consolidated pressure

The standalone hospital result was more resilient. Revenue grew by Rs1.027 billion and profit after tax increased by Rs60.9 million. Standalone net margin nevertheless eased to approximately 9.31% from 9.76%, showing that even the core company converted slightly less of each revenue rupee into net profit.

The consolidated outcome was materially weaker. Total group net margin fell to 5.48% from 9.74%. Profit attributable to the parent was about Rs199.6 million below standalone profit after tax. This gap reflects subsidiary and consolidation effects, but the currently accessible disclosures do not provide a sufficiently detailed Q1 subsidiary bridge to identify the exact contribution of Shifa National Hospital Faisalabad, SIHT, Shifa Development Services or intercompany eliminations.

That limitation is decision-relevant. The group is expanding through new facilities and integrated services, so a period of higher start-up and operating costs can occur before new capacity reaches an efficient scale. However, the filing does not quantify that explanation for Q1. It should be treated as a hypothesis to test in future disclosures, not as a stated cause of the current decline.

What improved

Revenue growth remained strong on both reporting bases. Consolidated growth of 22.2% exceeded standalone growth of 13.5%, indicating that subsidiaries and the broader network added meaningful activity. This is consistent with the company’s FY2026 strategy of expanding care outside the Islamabad flagship hospital, although the current quarter does not disclose a facility-by-facility revenue split.

The group’s cash and bank balances increased 4.8% from June 2026 to Rs2.916 billion. Current assets rose 10.0% to Rs8.782 billion, faster than the 5.5% increase in current liabilities to Rs7.248 billion. The current ratio therefore improved to about 1.21 times from 1.16 times.

Equity increased 2.5% to Rs20.510 billion. The group remained net-debt positive only modestly relative to its equity base: total debt of Rs3.485 billion less cash of Rs2.916 billion produced approximate net debt of Rs568.5 million. This balance-sheet capacity provides some room for healthcare investment, but the direction of debt still warrants attention.

What weakened or needs attention

Margin compression is the clearest concern. The 659-basis-point fall in consolidated gross margin more than offset the benefit of higher revenue. Unless the group discloses a credible path toward better utilisation or cost absorption, the growth will continue to look expensive.

Debt increased 9.7% from June 2026 to Rs3.485 billion, while cash rose more slowly. Approximate net debt increased from Rs391.5 million to Rs568.5 million. Finance cost also rose sharply year on year, so the balance-sheet movement already has an earnings consequence.

Working capital expanded. Inventory rose 28.2% to Rs1.328 billion and trade receivables increased 12.1% to Rs2.144 billion. Trade and other payables increased 5.8% to Rs6.580 billion. The published result does not provide a detailed current-quarter cash-flow bridge in the evidence used here, so this article does not claim that accounting profit converted into cash at the same rate.

The consolidated tax charge fell broadly in line with pre-tax profit, but the core issue arose before tax. The fall in gross and operating profitability cannot be explained away by a one-off tax movement.

No Q1 operational KPIs were available for occupancy, available beds, occupied bed days, inpatient admissions, outpatient visits or tariff mix. Those omissions do not invalidate the earnings analysis, but they prevent a firm conclusion on whether the margin decline came from start-up costs, lower utilisation, clinical mix, staff costs, supplies or pricing.

Historical operating context

For FY2026, the standalone company reported revenue of Rs30.284 billion, up 8.3%, and profit after tax of Rs2.793 billion, up 19.9%. Management attributed the annual improvement to stable operations, process optimisation, cost management and disciplined financial oversight. Those comments describe the year ended June 30, 2026 and should not be reused as a direct explanation for Q1 FY2027.

The FY2026 annual report shows the Islamabad H-8 hospital at 63.06% room occupancy, broadly unchanged from 63.57% a year earlier. Shifa National Hospital Faisalabad had 25.17% occupancy on the consolidated basis, down from 33.44%, although its available bed days increased as the facility’s operating footprint expanded. These are annual figures, not current-quarter occupancy data.

The annual report also shows why the consolidated basis is increasingly important. Shifa National Hospital Faisalabad commenced operations, the Bahria Town medical centre became operational and the PET-CT facility became fully functional. Management’s forward pipeline includes further Faisalabad growth, Shifa Medical Center Islamabad, a proposed Mirpur project, SPECT-CT and refractive-surgery equipment, and other capacity enhancements.

The October 22 corporate briefing notice confirms management’s engagement with investors after the annual result, but the notice itself does not contain operating guidance. The FY2026 corporate briefing material highlighted standalone revenue of Rs30.284 billion, profit after tax of Rs2.793 billion, EPS of Rs44.12 and a proposed Rs5 per share final dividend.

Why the expansion story still needs proof

Healthcare expansion can create a temporary mismatch: staff, equipment and facility costs arrive before patient volumes and specialised-service revenue reach mature levels. Shifa’s network projects make that a plausible analytical interpretation. Yet the Q1 filing does not quantify start-up losses, facility-level margins or utilisation, so it would be wrong to present the interpretation as a reported company fact.

The proof should come through three observable results: rising occupancy and patient throughput at newer facilities, recovery in consolidated gross margin, and a narrowing gap between standalone profit and consolidated profit attributable to shareholders. Until then, the expansion is strategically visible but its near-term earnings quality remains uncertain.

AlphaGen model scores

The following are AlphaGen model outputs, not company-reported figures and not investment advice:

  • Alpha QoQ Score: 26.63
  • TTM Performance Score: 16.78
  • 3Y Business Perf Score: 84.38
  • Sector Leadership Score: 38.61

The score pattern is coherent with the evidence: weak quarter-on-quarter and trailing performance contrasts with a strong three-year business record, while sector leadership remains below the midpoint. The models are signals for further research, not substitutes for the financial statements.

What to monitor next

  • Consolidated gross margin: whether it recovers from 9.55% and whether management provides a facility-level cost and utilisation bridge.
  • Standalone versus consolidated profit: whether new operations move toward breakeven and reduce the roughly Rs200 million gap between standalone PAT and parent-attributable consolidated profit.
  • Faisalabad and new facilities: occupancy, patient throughput, service mix and the timing of further capacity additions.
  • Debt and finance cost: whether higher borrowings are temporary project funding or become a persistent drag on earnings.
  • Working capital: the reasons for the 28% increase in inventory and 12% increase in receivables since June.
  • Capital deployment: progress on Shifa Medical Center Islamabad, Mirpur, SPECT-CT and other projects, with clear commissioning dates and evidence of demand.

Overall, Q1 FY2027 confirmed that Shifa’s network is growing, but it also exposed the cost of that growth. The standalone hospital remained profitable and expanded, while consolidated margins and earnings weakened sharply. The next quarter must show whether this was a temporary cost-absorption phase or the start of a lower-margin group structure. For now, the most defensible verdict is operational expansion with materially weaker consolidated earnings quality.

Primary sources